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Background: Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of childbearing
age, and it seems better to consider it as an ovarian manifestation of metabolic syndrome. The aim of the current
study was to evaluate early atherosclerotic findings in patients with PCOS.
Methods: We enrolled 46 women with PCOS and 45 normal control subjects who were referred to our hospital’s
endocrinology outpatient clinic. Carotid intima media thickness (CIMT) and flow-mediated dilatation (FMD) were
performed in both cases and matched controls.
Results: Patients with PCOS showed an increased mean CIMT (0.63 ± 0.16 mm) when compared with the control
subjects (0.33 ± 0.06 mm). This difference was statistically significant (p = 0.001). The mean FMD in young patients
with PCOS was 10.07 ± 1.2%, while it was 6.5 ± 2.06% in normal subjects. This difference was also statistically
significant (p = 0.001).
Conclusion: Our findings suggest that PCOS is related with early atherosclerotic findings.
Background
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy in women of childbearing age, and it
seems better to consider it as an ovarian manifestation of
metabolic syndrome (MS) [1,2]. MS has already been con-
firmed as part of the tsunami of cardiovascular risk factors
(obesity, lipid abnormalities, impaired glucose tolerance
and hypertension) [3]. Insulin resistance is considered as
the basic pathophysiological mechanism in MS, and is also
a well-recognised presentation of PCOS [4]. However,
data regarding endothelial function impairment as an indi-
cator of increased risk of cardiovascular disease in PCOS
are still controversial [5,6], with some studies saying that
PCOS-induced insulin resistance does not show endothe-
lial dysfunction [7]. The aim of our study was to assess
and compare the endothelial function as a predictor of
cardiovascular risk by measuring flow-mediated dilatation
in young women with PCOS and matched control
subjects.
Method
Before the beginning of the study, its protocol was
approved by the University Ethics Committee and the
Faculty of Medicine. Written informed consent was
obtained from each participant. We enrolled 46 women
with PCOS and 45 normal control subjects who were
referred to our hospital’s endocrinology outpatient clinic.
The patients and controls were selected from the normo-
tensive population with a body mass index (BMI) less
than 27 kg/m2. Women with diabetes mellitus, cases of
hypertension and those with age above 30 years and BMI
above 27 kg/m2 were excluded from study.
The diagnosis of PCOS was documented based on a his-
tory of oligomenorrhoea or amenorrhoea (less than eight
cycles per year), clinical or biochemical manifestations of
hyperandrogenism such as hirsutism, acne or elevation of
at least one circulating ovarian androgen (serum dehy-
droepiandrosterone sulphate [DHEAS] or testosterone)
and polycystic ovaries at ultrasound. Two of three criteria
were sufficient to confirm the diagnosis. Controls were
healthy women with normal menstrual cycles, non-hyper-
androgenic, non-hirsute and with normal ovarian mor-
phology at ultrasound. One examiner (M.A.) assessed the* Correspondence: Mohamadi_afshin@yahoo.com1Department of Radiology, Urmia University of Medical Sciences, Urmia, Iran
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hirsutism according to Ferriman-Gallwey score; a score
greater than 7 was considered to indicate hirsutism.
All those with secondary causes of hyperandrogenism,
such as hyperprolactinaemia, thyroid disease, late onset
congenital adrenal hyperplasia (17-OH progesterone > 2
ng/dl), androgenic tumour (testosterone > 4 ng/ml), Cush-
ing disease, renal or liver failure, pregnancy and diabetes
mellitus, were excluded from the study. After basic history
taking, anthropometric properties of cases and controls
such as BMI, waist circumference (WC), hip circumfer-
ence (HC), ratio of WC/HC and systolic and diastolic
blood pressure were measured.
Fasting blood samples were collected for measurement
of blood glucose, insulin, androgens, triglycerides (TG),
total cholesterol (TC), high-density lipoprotein (HDL) and
low-density lipoprotein (LDL). Insulin resistance (IR) was
assessed using both fasting insulin levels and the homeos-
tasis model assessment (HOMA) calculation: fasting
serum insulin (micro units per millilitre) multiplied by
fasting plasma glucose (millimoles per litre) and divided
by 22.5.
The serum levels of DHEAS, follicle-stimulating hor-
mone (FSH), luteinising hormone (LH), 17 hydroxy
(OH) progesterone, testosterone and prolactin were also
measured in cases and controls.
CIMT measurement
High-resolution B mode ultrasonographies of both the
common and internal carotid arteries were performed
with an ultrasound device (Siemens, Sonoline G40,
Germany) equipped with a 10 MHz linear array transdu-
cer. Patients were examined in the supine position with
the head tilted backwards. After the carotid arteries were
located by transverse scan, the probe was rotated 90° to
obtain and record a longitudinal image of common carotid
arteries.
The maximum CIMT was measured at the posterior
wall of the common carotid artery, 2 cm before the bifur-
cation, as the distance between first and second echogenic
lines of anterior and posterior arterial walls. The image
was focused on the posterior wall of the common carotid
artery, and we used the gain settings to optimise the qual-
ity of the image. For accuracy, the CIMT measurements
were performed vertical to the arterial wall. Three CIMT
measurements were taken at each site and the average
measurement was calculated and used.
Flow-mediated dilatation (FMD) measurement
Ultrasound examination of FMD was performed in the
morning after overnight fast, after 15 minutes rest in the
horizontal position, by means of a Sonoline G40 ultra-
sound scanner (Siemens, Germany) with a linear transdu-
cer (10 MHz). The diameter of the right brachial artery
was measured 3-5 cm above the antecubital space at
baseline. The measurement was performed in the end-
diastolic phase, marking the diameter between anterior
and posterior artery wall in the zone between the media
and adventitia (’m-line’). An average of three measure-
ments was taken and further analysed to calculate FMD.
Subsequently, a pneumatic tourniquet was placed on the
upper part of the right forearm and inflated for four min-
utes to a pressure of 200 mm Hg or 50 mm Hg above sys-
temic arterial blood pressure. Sixty seconds after cuff
release, the diameter of the right brachial artery was mea-
sured three times. FMD was calculated as an increase of
vascular diameter (in percentage) from the difference
between maximum and baseline brachial artery diameter.
Data were calculated as absolute diameter of the brachial
artery (in mm) and percentage increased in the diameter
of the brachial artery. CIMT and FMD in all cases and
controls were measured by one radiologist (A.M.), who
was blinded to clinical and laboratory data of patients and
controls.
Statistical analysis was performed using SPSS (version
16. Chicago, IL, USA). We performed the statistical calcu-
lation by using the T-test, Mann-Whitney U test, Kolmo-
gorov-Smirnov (K-S) test and logistic regression. A p value
equal or less than 0.05 was considered statistically
significant.
Results
The mean ± SD of age was 23.02 ± 5.17 in the patient
group and 27.96 ± 3.97 in the control group. The mean ±
SD of BMI in PCOS was 25.08 ± 5.54 kg/m2, and in con-
trol subjects it was 21.59 ± 3.08 kg/m2. There were statisti-
cally significant differences in age, BMI, AC, HC and ratio
of AC/HC between cases and control subjects. Table 1
summarises the anthropometrics data of PCOS and con-
trol subjects.
Table 1 This table shows the anthropometric data of the
cases and controls
Variable Group Number Mean ± SD P value
Age Control 45 27.96 ± 3.97 0.000
PCOS 46 23.02 ± 5.17
Height Control 45 163.78 ± 3.80 0.03
PCOS 46 161.43 ± 6.40
Weight Control 45 58.73 ± 7.44 0.008
PCOS 46 65.60 ± 15.25
BMI Control 45 21.59 ± 3.80 0.001
PCOS 46 25.80 ± 5.45
AC Control 45 80.16 ± 12.76 0.65
PCOS 46 81.61 ± 12.86
HC Control 45 97.87 ± 6.20 0.003
PCOS 46 105.96 ± 16.46
WC/HC Control 45 0.82 ± 0.4 0.02
PCOS 46 0.79 ± 0.09
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The mean systolic blood pressure (SBP) and diastolic
blood pressure (DBP) in PCOS patients and control sub-
jects were 114.46 ± 29.02 mm/Hg, 79.02 ± 8.40 mm/Hg
and 120.67 ± 18.26 mm/Hg, 78.40 ± 7.37 mm/Hg, respec-
tively. There was no statistically significant difference
between PCOS and controls in terms of SBP and DBP.
There were statistically significant differences in terms of
FBS, TG, TC, LDL and HDL between PCOS and control
subjects. Table 2 summarises the SBP, DBP and biochem-
ical data of PCOS patients and control subjects.
Assessment of sex hormone and insulin levels between
PCOS and control subjects showed that there was a signif-
icant difference in term of FSH, prolactin (PRL), testoster-
one and DHEAS between cases and controls, but there
were no significant differences between cases and controls
in term of LH and 17 OH progesterone levels. Table 3
summarises the serum insulin and sex hormone levels in
PCOS patients and controls.
Patients with PCOS demonstrated higher HOMA index
levels of (2.77 ± 1.80 vs. 0.81 ± 0.08; p < 0.000) when com-
pared with the control subjects. Furthermore, patients
with PCOS showed an increased mean CIMT (0.63 ± 0.16
mm) when compared with the control subjects (0.33 ±
0.06 mm). This difference was statistically significant
(p = 0.001).
The mean ± SD of brachial artery diameter at baseline
was 3.89 ± 0.19 mm in normal subjects and 3.86 ± 0.11
mm in the PCOS group. The difference was not statisti-
cally significant (p = 0.19). Moreover, the mean ± SD of
brachial artery diameter post ischemia was 4.13 ± 0.17
mm in normal subjects and 4.23 ± 0.12 mm in the
PCOS group. The difference was statistically significant
(p = 0.01).
The mean FMD in young patients with PCOS was
10.07 ± 1.2% and 6.5 ± 2.06% in normal subjects. The dif-
ference was statistically significant (p = 0.001). On the
other hand, there was no significant association between
HOMA index and CIMT in PCOS patients (r = +0.13;
p = 0.18). The HOMA index of insulin resistance had a
significantly negative relation with FMD in PCOS
patients (r = -0.3; p = 0.02).
Discussion
The endothelium is considered the largest endocrine
gland, and secretes many transmitters to maintain the
homeostasis of the circulatory system [8]. FMD is a non-
invasive US method currently recognised as a useful
technique for the evaluation of endothelial function [8].
The basic mechanism of FMD is the evaluation of bra-
chial artery dilatation by evoking brachial artery ischemia.
After brachial artery occlusion, endothelial nitric oxide is
released and vascular smooth muscle relaxation occurs
[9].
One of the early processes in the pathophysiology of
atherosclerosis is impaired endothelial function [10].
Impaired endothelial function which is quantified by FMD
is a marker of increased cardiovascular risk because it is
well correlated with impaired endothelial function in cor-
onary arteries [11]. The exact effect of PCOS on endothe-
lial function remains controversial. Several studies have
revealed that it is not impaired in women with PCOS who
are either not obese or do not display morbid obesity
[7,12,13]. However, some authors believe that endothelial
function is impaired in patients with PCOS [5,14,15]. In
our investigation, we evaluated vascular function in sub-
jects with PCOS, and compared those patients with
healthy control subjects.
Our study demonstrates a significant difference in CIMT
between both age-matched PCOS and control subjects.
Our result is in agreement with the report by Lukhani [16]
and Talbott et al. [17] but is in contrast with the study of
the Meyer et al. [4]. Our study demonstrates a significant
difference in FMD between both PCOS and control
groups, which is in agreement [9,18] and in contrast
[7,19-22] with other studies. Orio et al showed that a
significant difference in flow-mediated dilation and in
intima-media thickness in young, normal-weight, nondy-
slipidemic, nonhypertensive women with PCOS in com-
parison with control subjects [14]. Although they excluded
patients with dyslipidemia and hypertension from study
group but our results are in concordance to the report by
them.
Our results provide additional evidence confirming
that there is endothelial dysfunction in women with
PCOS in comparison with normal subjects.
The pathophysiological mechanism of inducing
endothelial dysfunction remains unclear, but insulin
resistance seems to be essential. Beckman et al. [7]
reported an association between insulin resistance and
endothelial dysfunction in type 2 DM and lipodystrophic
diabetes. Others have shown an association between
insulin resistance in children with DM and MS [23,24].
Table 2 This table shows the systolic and diastolic blood
pressure and biochemical data of the cases and controls
SBP (mm/Hg) Controls 45 120.67 ± 18.26 0.22
Cases 46 114.46 ± 29.02
DBP (mm/Hg) Controls 45 78.44 ± 7.37 0.72
Cases 46 79.02 ± 8.40
FBS (mg/dl) Controls 45 74.73 ± 9.28 0.0001
Cases 46 85 ± 8.67
TG (mg/dl) Controls 45 98.76 ± 48.90 0.04
Cases 46 123.02 ± 62.70
LDL (mg/dl) Controls 45 118.79 ± 31.76 0.05
Cases 46 133.43 ± 40.24
HDL (mg/dl) Controls 45 60.16 ± 13.16 0.0001
Cases 46 47.49 ± 8.41
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The postulated mechanisms whereby insulin resistance
can adversely affect the endothelium are: overproduction
of free fatty acids; tumour necrosis factor (TNF) a; lep-
tin, which causes endothelial dysfunction; and the
induction of an increased oxidative stress mechanism
that, contributes to endothelial dysfunction [4,25,26].
In our study, there was a statistically significant differ-
ence in terms of BMI between PCOS and control sub-
jects (both groups had normal BMI but the difference
between them was statistically significant). Previous stu-
dies reported that the endothelial function was preserved
in lean individuals and without morbid obesity with
PCOS [8,13], but this still remains controversial [6,14,15].
We accept the lack of BMI matching as a limitation of
our study, and recommend its consideration in future
research.
Although in our study, the mean CIMT was different
between PCOS and normal subjects, the HOMA index
was correlated with FMD and we did not find a relation-
ship between the HOMA index and CIMT. A previous
study revealed that endothelial dysfunction occurred
early in the development of atherosclerosis, preceding
the onset of increased CIMT [27]. Thus, it seems that
various risk factors in PCOS patients may contribute
separately to the development of endothelial dysfunction.
We found that young patients with PCOS had higher
levels of MS inclusion criteria such as serum TG, TC,
LDL, FBS, insulin, insulin resistance (HOMA-IR) and
lower levels of serum HDL. Thus, we believe it is better
to consider PCOS as an ovarian manifestation of MS.
In conclusion, PCOS accompanies the tsunami of MS
and hormonal abnormalities such as insulin resistance,
dyslipidaemia, hyperandrogenaemia all make PCOS
patients susceptible to future cardiovascular events. The
diagnosis of this entity may offer an early cardio-protective
protocol for women with PCOS.
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